Relief Therapeutics Holding AG (RLFTF)

[SF Wolf]

COVID-19 drug remdesivir may prolong hospital stay, researchers claim

The study on veterans hospitalized with COVID-19 concluded that remdesivir was not associated with improved survival

https://www.foxnews.com/health/covid-19-drug-remdesivir-may-prolong-hospital-stay-researchers-claim

This bodes well for the NIH sponsored Clinical Trial of Aviptadil and Remdesivir:

NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

April 5, 2021
In this article:

RLFTF

RADNOR, Pa., April 6, 2021 /PRNewswire/ -- NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries. Aviptadil is being developed by NeuroRx as ZYESAMI™ in collaboration with Relief Therapeutics Holding, AG (SIX: RLF, OTCQB: RLFTF).

The trial, designated as TESICO (Therapeutics for Severely Ill Inpatients with COVID-19), is funded by the US Government COVID-19 Therapeutics Response and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The TESICO protocol has been reviewed and approved as a phase III trial by the US Food and Drug Administration and will randomly allocate 640 participants to Aviptadil, Remdesivir, the combination of both drugs and placebo.

Remdesivir is currently marketed as Veklury© by Gilead Sciences (Nasdaq: GILD). The primary endpoint of the trial will be participant recovery from respiratory failure over 90 days. Additional information will be supplied by the NIH when the trial randomizes its first patients.

https://finance.yahoo.com/news/neurorx-announces-zyesami-aviptadil-selected-050100868.html